Phillip Parente
Overview
Explore the profile of Phillip Parente including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
832
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Soon J, Anton A, Torres J, Lawrence R, Parente P, McKendrick J, et al.
Support Care Cancer
. 2018 Oct;
27(2):373-382.
PMID: 30350189
Purpose: Testicular seminomas occur in young men and are highly curable. Toxicities following treatment for men with extensive stage II-III seminomas may cause long-term morbidities. However, it is not clear...
32.
Dennett A, Shields N, Peiris C, Prendergast L, OHalloran P, Parente P, et al.
J Physiother
. 2018 Sep;
64(4):255-263.
PMID: 30217412
Question: Does adding weekly, physiotherapist-delivered motivational interviewing to outpatient oncology rehabilitation for cancer survivors increase physical activity levels and improve physical and psychosocial outcomes that are typically impaired in this...
33.
Ugalde A, OCallaghan C, Byard C, Brean S, MacKay J, Boltong A, et al.
Support Care Cancer
. 2018 May;
26(11):3765-3771.
PMID: 29749585
Purpose: While advance care planning holds promise, uptake is variable and it is unclear how well people engage with or comprehend advance care planning. The objective of this study was...
34.
Lee D, Isobe H, Wirtz H, Aleixo S, Parente P, de Marinis F, et al.
BMC Health Serv Res
. 2018 Mar;
18(1):147.
PMID: 29490654
Background: Data are scarce regarding real-world health care resource use (HCRU) for non-small cell lung cancer (NSCLC). An understanding of current clinical practices and HCRU is needed to provide a...
35.
Yau W, Devitt B, Aung S, Parente P, Sharma S, Pezaro C
Intern Med J
. 2018 Feb;
48(2):230-231.
PMID: 29415353
No abstract available.
36.
To S, Kwan E, Fettke H, Mant A, Docanto M, Martelotto L, et al.
Eur Urol
. 2018 Feb;
73(6):818-821.
PMID: 29398263
Patient Summary: Detection of androgen receptor splice variants (AR-Vs) in circulating tumour cells of advanced prostate cancer patients has been linked to resistance to abiraterone and enzalutamide. We designed a...
37.
Yuen E, Knight T, Dodson S, Chirgwin J, Busija L, Ricciardelli L, et al.
Health Soc Care Community
. 2017 Dec;
26(3):330-344.
PMID: 29210140
Caregivers have been largely neglected in health literacy measurement. We assess the construct validity, and internal consistency of the Health Literacy of Caregivers Scale-Cancer (HLCS-C), and present a revised, psychometrically...
38.
Aung S, Parente P, McKendrick J
World J Oncol
. 2017 Nov;
5(3):149-152.
PMID: 29147395
Adrenocortical carcinomas (ACCs) are rare and often aggressive with more than 50% of the cases already in stage III-IV (ENSAT) at the time of diagnosis. Nearly 60% of ACCs present...
39.
Delahunty R, Lee M, Datta M, Parente P
BMJ Case Rep
. 2017 Oct;
2017.
PMID: 29054936
No abstract available.
40.
Eisenberger M, Hardy-Bessard A, Kim C, Geczi L, Ford D, Mourey L, et al.
J Clin Oncol
. 2017 Aug;
35(28):3198-3206.
PMID: 28809610
Purpose Cabazitaxel 25 mg/m (C25) significantly improved overall survival (OS) versus mitoxantrone ( P < .001) in postdocetaxel patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase III TROPIC...